分子靶向抗肿瘤药物皮肤不良反应研究进展  

Advance of skin adverse reactions caused by molecular targeted anti-tumor drugs

作　　者：石艾秀 曹双林[2] SHI Aixiu;CAO Shuanglin(Department of Dermatology,Suqian First Hospital,Suqian 223800,China;Department of Dermatology,Affiliated Hospital of Nantong University,Nantong 226001,China)

机构地区：[1]宿迁市第一人民医院皮肤科,江苏宿迁223800 [2]南通大学附属医院皮肤科,江苏南通226001

出　　处：《中国麻风皮肤病杂志》2021年第9期605-609,共5页China Journal of Leprosy and Skin Diseases

摘　　要：近年来靶向抗肿瘤药物的使用在恶性肿瘤治疗中逐渐广泛,显著提高了患者生存率,但其引起的皮肤不良反应十分常见。根据作用靶点的不同对靶向药物不良反应进行分类分析,可找出其中的共性与个性,为皮肤科及肿瘤科医生提供诊疗的新思路。本文将分别从细胞膜相关抑制剂、胞内信号通路抑制剂及免疫检测点抑制剂三个方面综述临床上较为常见的靶向药物相关皮肤不良反应的类型及其处理措施。In recent years,the use of targeted anti-tumor drugs has gradually occupied a pivotal position in the treatment of malignant tumors.The widespread application of targeted therapies can significantly improve the survival rate of patients,but the adverse skin reactions(ASR)caused by them are common.Classification and analysis of ASR caused by targeted drugs according to different targets can find commonalities and personalities,and provide new ideas for diagnosis and treatment for dermatologists and oncologists.The types of ASR caused by targeted drugs and their treatment measures of cell membrane-related inhibitors,intracellular signaling inhibitors,and immune checkpoint inhibitors are reviewed in this article.

关 键 词：靶向治疗 免疫治疗 不良反应 皮肤 

分 类 号：R730.51[医药卫生—肿瘤]